Irish drugmaker Allergan reported weaker-than-expected quarterly revenue after its Alzheimer's drug Namenda IR lost patent exclusivity and the company cut its full-year revenue forecast.
Allergan, known as Actavis until it bought Botox maker Allergan last year and took on its name, cut its forecast for adjusted full-year net revenue to $14.65 billion to $14.90 billion (€13.22 billion to €13.45 billion), from its prior estimate of $17 billion.
The company’s quarterly net revenue rose marginally, to $3.68 billion from $3.63 billion a year earlier, but this was far below the average Wall Street estimate of $4.08 billion.
Net loss
Dublin-based Allergan’s net loss attributable to ordinary shareholders increased to $571.3 million, or $1.44 per share, for the second quarter ended June 30th, from $312.7 million, or 80 cents per share, a year earlier.
Excluding special items, the company earned $3.35 per share, beating the average analysts’ estimate by 1 cent, according to Thomson Reuters I/B/E/S.
Allergan’s shares were down 0.7 per cent in light premarket trading on Monday. Up to Friday’s close of $253.85, the stock had fallen nearly 19 per cent this year.
Inversion deals
Pfizer dropped plans to buy Allergan for $160 billion in April after the US government cracked down on so-called inversion deals, in which companies move their domicile to countries that have a lower tax rate.
The combination would have been the biggest deal ever in the pharmaceutical industry.
Allergan said last week it would sell its Anda distribution business for $500 million to Teva Pharmaceutical Industries, a day after the Israeli drugmaker completed the $40.5 billion acquisition of Allergan's generic-drug portfolio.
